intellim Holdings Corporation Concluded the Partnership Agreement with Bangkok Hospital Chiang Mai

This is to inform you that intellim Holdings Corporation (President & CEO: Masakuni Ukita/Tokyo Head Office: Taito-ku, Tokyo) held a signing ceremony with Bangkok Hospital Chiang Mai on November 27, 2019, in order to introduce Japanese companies considering clinical trials in Thailand.

1.Background

In July of this year, following the announcement from the Ministry of Health, Labor and Welfare that Thailand adopted the Japanese Pharmacopoeia as their reference pharmacopoeia, Japanese pharmaceutical companies considering drug exports to and new drug developments in Southeast Asia have been increasing. Although many clinical trials have been conducted in facilities in Thailand, there are many issues, such as ensuring subjects to continue their participation, sudden changes in regulations, and protocol deviations, etc.
This time, intellim will work to solve these issues through the partnership agreement with Bangkok Hospital Chiang Mai.

2.Purposes

1. Establish a new anti-cancer drug clinical trial system with Japanese high quality standards in a facility having high efficiency of conducting clinical trials in Thailand.
2. Conduct high-quality clinical trials in Bangkok Hospital Chiang Mai where there has many patients with high compliance
3. Work on advanced treatment under the guidance of Professor Thongprasert, who is the No. 1 oncology expert in Southeast Asia (see Note 1)

3.About Bangkok Hospital Chiang Mai

The Bangkok Hospital Chiang Mai belongs to the BDMS Group (Bangkok Dusit Medical Services): the largest medical network in Thailand and can provide top-level medical standards and leading-edge technologies. The BDMS has 12,747 doctors in the whole group, the director of Major General Niwat Boonyuen of the Bangkok Hospital Chiang Mai, where they were supporting this signing ceremony, is also the vice president of the BDMS Group 4.

Bangkok Hospital Chiang Mai
88/8-9 Moo 6 Nong Pa Khrang,
Mueang Chiang Mai, Chiang Mai 50000. https://www.bangkokhospital-chiangmai.com/en/(This will open in a new window.)

As the first global CRO from Japan that can support the world in new drug development in the future, we will still be making efforts for speedy expansion of Japanese drug development in Asia.

※Note 1

Professor Dr. Sumitra Thongprasert　（ศ. พญ. สุมิตรา ทองประเสริฐ）
・Director of the Cancer Center of Excellence of Bangkok Hospital Chiang Mai
・Emerita Professor of the Medical Oncology Division of Chiang Mai University

She worked on various educational programs for oncologists, nurses, and pharmacists, etc. in Bangkok Hospital Chiang Mai. She participated in domestic and global clinical trials especially in the area of lung cancer, and established the standardization of treatment in Thailand.

2018	：	Received the 5th Kobayashi Foundation Award from Kobayashi Foundation of Cancer Research (In recognition for Achievement in Developing an Oncology Network through Education, Research, Society, and Region）
2016	：	Received the ESMO Women for Oncology from European Society for Medical Oncology (ESMO) (In recognition of Achievement as Outstanding Female Oncologist)

She is a member of domestic and international academic societies, while involving in lung cancer treatment and researches and publishing many academic papers.